Other risk factors for AKI in patients receiving TMP/SMX include concomitant angiotensin converting enzyme inhibitor (OR 2.36, 95% CI 1.01–5.24), potassium supplementation (OR 4.10, 95% CI 1.45–10.10), and elevated baseline SCr (OR 2110, 95% CI 724–7980) [92]. The gene discussed is ACE; the disease is acute kidney injury.